NASDAQ
No price data available for this timeframe.
Apogee Therapeutics, Inc. (APGE) has had 39 insider transactions recently, with net insider activity of -$143K (net selling). The most active insider is Fairmount Funds Management LLC (Director).
Total Transactions
39
10 buys /29 sells
Shares Acquired
61,317
Transactions: 10•Avg: 6,131.7
Shares Disposed
204,275
Transactions: 29•Avg: 7,043.97
Net Activity
-142,958
Net Selling•Ratio: 34.48%
Q2 2026(Current) | 61,317 | 204,275 | -142,958 | 34.48% |
Q1 2026 | 442,671 | 1,875,975 | -1,433,304 | 15.38% |
Q4 2025 | 376,298 | 124,740 | +251,558 | 14.29% |
Q3 2025 | 7,365 | 22,905 | -15,540 | 14.29% |
Q2 2025 | 101,227 | 9,310 | +91,917 | 140.00% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q2 2026
Acquired vs Disposed Shares
Net Distribution: 142,958 shares•Acquired/Disposed Ratio: 34.48%
Net Activity | |||||
|---|---|---|---|---|---|
FFML Fairmount Funds Management LLC | Director | 2 | 7,657 | 1,750,000 | -1,742,343 |
HJ Henderson Jane | Officer: chief financial officer | 23 | 83,690 | 27,500 | +56,190 |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | 35 | 256,016 | 283,000 | -26,984 |
SNP Shah Nimish P | Director | 1 | 7,657 | 0 | +7,657 |
MMC McKenna Mark C. | Director | 1 | 7,657 | 0 | +7,657 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2026-06-22 | Officer: chief medical officer | Sale | 26,400 | $132.6 | $3,500,640 | 179,248 | |
2026-06-22 | Director, officer: chief executive officer | Sale | 80,000 | $132.54 | $10,603,200 | 1,015,987 | |
2026-06-10 | Director, officer: chief executive officer | Sale | 6,770 | $82.21 | $556,561.7 | 1,109,217 | |
2026-06-10 | Director, officer: chief executive officer | Sale | 7,654 | $82.78 | $633,598.12 | 1,101,563 | |
2026-06-10 | Director, officer: chief executive officer | Sale | 1,080 | $84.18 | $90,914.4 | 1,100,483 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
DC Dambkowski Carl | Officer: chief medical officer | Jun 24, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | Jun 24, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | Jun 12, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | Jun 12, 2026 | |
HMT HENDERSON MICHAEL THOMAS | Director, officer: chief executive officer | Jun 12, 2026 |
Net change in shares shown on right